<h1>The Stragen Group</h1> <h2>Pharmaceutical specialities</h2> <h3>Development, manufacturing and registration of special generic products.</h3><br> <h3>Strategy Generic</h3> The Stragen group started its activity in 1990 by participating in chemical factories in Italy and Norway.<br> After some years the Pharma generic activity was intensively developed using our expertise in selecting ÒnicheÓ products and obtaining the first marketing authorisations.<br> Recently we were able to create our own registration and distribution network in many European countries which gives us the opportunity to market our new products either directly or through licensees with long term supply agreements.<br> In the future we intend to continue registering injectable, oral or topical products in order to strengthen our presence in the generic market.<br> We have recently concluded an exclusive development and distribution agreement for our original molecule Homoharringtonine with ChemGenex Pharmaceuticals USA/Australia and also started the development of a new original CNS molecule.
© 2008 Stragen - All rights reserved |
Legal notice
|
Site map
